Eli Lilly Reports 52-Week Results Showing Improved Efficacy From TOGETHER-Psa Phase 3b Open-Label Clinical Trial Evaluating Taltz-Zepbound Combination In Psoriatic Arthritis

Nearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study

Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint

Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology 

INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. New detailed exploratory analyses showed treatment with Taltz and Zepbound used together maintained or further improved outcomes across disease activity, patient-reported and metabolic measures through Week 52. As previously reported, treatment with Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz alone at 36 Weeks. The 52-week findings were presented at the American College of Rheumatology (ACR) Convergence 2026 and simultaneously published in Arthritis & Rheumatology.  

At one year, nearly three times as many patients taking Taltz and Zepbound achieved ACR50, a measure reflecting at least a 50% reduction in PsA disease activity, compared to Taltz alone (43.7% of patients taking Taltz and Zepbound vs. 15.7% for Taltz alone). A greater proportion of patients achieving ACR50 was seen in the Taltz and Zepbound treatment arm as early as Week 4, before clinically meaningful weight loss was observed. Patient-reported outcomes, including physical function and fatigue, were maintained or further improved from Week 36 to Week 52 with Taltz and Zepbound vs. Taltz alone. In addition, Taltz and Zepbound were associated with improvements in body mass index (BMI), body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol vs. Taltz monotherapy.